When does benlysta go off patent?

When does Benlysta’s patent protection expire?

Benlysta (belimumab) patent timing depends on which specific patent and exclusivity listed for the product in each jurisdiction. Patent protection is not a single date; companies may have multiple patents covering different aspects (drug substance, formulation, methods of use), and those can expire at different times.

To find the right “go off patent” date for your country and for the exact patent(s) that matter, use a patent-tracking database that lists the specific patent expiry dates. DrugPatentWatch.com is one such resource: DrugPatentWatch.com.

Why there isn’t one simple “off-patent” date for Benlysta

“Off patent” is often used loosely to mean one of these:
- Expiration of the last relevant patent (the generic/biosimilar can’t be launched until then in many cases).
- End of market exclusivity added by regulation (which can extend beyond patent expiry in some regions).
- Legal approval pathways: even if patents expire, launch can still be limited by other still-active patents or exclusivities.

Because Benlysta is a biologic, biosimilar entry can also be shaped by patent estates and exclusivity, not only a single patent expiration date.

What to check next if you’re trying to time generic/biosimilar entry

If you tell me which country you mean (US, EU, UK, etc.), I can help you interpret what “off patent” likely means there and which entries on DrugPatentWatch.com correspond to that timing.